STUDresearch · Peptide
AHK-Cu
Also known as
AHK copper peptide · Ala-His-Lys copper · AHK-Cu copper tripeptide · L-alanyl-L-histidyl-L-lysine-Cu2+ · copper AHK · copper tripeptide-3 (cosmetic INCI / supplier contexts) · tripeptide-copper complex (AHK context) · Ala-His-Lys-Cu
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Peptide
Niche talk
Local
Topical / Injection
Skin, hair & tissue remodeling
Mainly topical scalp use; sparse injection accounts describe a different, poorly characterized exposure.
What people say
A hair/scalp copper peptide discussed mainly as a topical serum, often alongside other hair treatments. AHK-Cu is not GHK-Cu, and the foundational follicle paper was a culture study—not an injection trial.
Doses people talk about
The rows describe distinct community and cosmetic ranges, not a progression. Higher historical percentages, injection charts and their cautions remain in the full notes; culture bath concentrations do not validate a scalp percentage.
How it may feel
Early talk is about tingling, dryness or tint; hair reports take weeks to months and include both apparent thickening and no change. Needling, minoxidil and other treatments often obscure what AHK contributed.
DIY topical discussion~0.1–1%; once or twice daily is discussed
Reported volume ranges from 2–5 drops to ~0.25–1 mL per application. Powder cost, irritation and extrapolation drive the differing concentrations.
Lower daily-serum reports~0.05–0.2% topical
If w/v, this means 0.5–2 mg/mL. The often-repeated 1–2 mg/mL comparison covers only 0.1–0.2%, not the full band.
Cosmetic use-level context~0.3–1% in finished formulations
Supplier ranges differ from finished-product guides around 0.5–1% (broader 0.3–2%). They do not establish gray-powder or injection safety.
Half-life & effect duration
- Half-life in the body
- Topical or injectedNo settled estimate
- Felt duration people report
- Hair reportsChanges after 2–3 months with other treatments; no change at 2 months in another account
Cycles people discuss
Topical discussions describe ongoing daily use, often judged over 3–6+ months, with pauses for irritation or stopping after no benefit. Those are observation habits, not an established on/off cycle.
Timing
Evening use or once-/twice-daily routines are discussed, sometimes separating minoxidil morning and copper evening. The 15–20-minute layering convention is not a measured absorption window.
Stacks
GHK-Cu, needling, minoxidil and anti-androgens are frequent companions in these notes; combinations make the hair-result credit hard to separate.
Access talk
Not on the July 2026 peptide ballot. PCAC that week was BPC/KPV/TB-500 and neighbors. AHK-Cu is not that story.
Watch for
Local irritation: Redness, sting, itch, dryness, flaking — most named topical downside; worse at high DIY % or on broken/needled skin.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
A human AHK-Cu half-life is not established by the sources checked here.
The foundational paper exposed isolated follicles and cultured cells. It did not measure drug clearance after applying a scalp serum or injecting AHK-Cu.
No numeric topical or injection estimate is assigned; GHK-Cu, culture exposure and cosmetic shelf life are different questions.
- Pyo et al. — AHK-Cu in cultured human follicles (opens in a new tab)Original abstract, PMID 17703734, accessed through Europe PMC core API on September 6: isolated human follicles and cultured dermal papilla cells; 10^-12–10^-9 M; apoptosis result.Abstract only; ex-vivo/in-vitro exposure, not living scalp application or injection PK. The reduction in apoptotic cell count was not statistically significant. No human parent half-life was measured here; detailed historical high-concentration figures are not independently recertified.
Felt duration people report
Hair-result reports span weeks to months, with both positive and null accounts.
One poster described changes after 2–3 months with needling, minoxidil and alfatradiol; another reported none at two months. These do not define how long one application feels active.
Uncontrolled, unverified and confounded; no single-application duration or clean washout. Injection reports are separate and include uncertain benefit.
- Topical AHK-Cu report with its full hair-treatment stack (opens in a new tab)Actual July 29, 2026 comment by nukesaregay, including its final paragraph: 2–3 months daily topical use, changes in the past month, needling six weeks, minoxidil a decade and alfatradiol a year; visible follow-up replies.Single unverified report; concomitant treatments and hair-cycle fluctuation prevent attribution. Planned finasteride addition is not a completed outcome. No single-application duration or blood PK.
- AHK-Cu versus GHK-Cu — topical null report (opens in a new tab)Actual April 18, 2026 Wonderful_Bass304 comment: raw AHK-Cu in hair tonic sprayed on the scalp for about two months without a noticeable change; surrounding discussion inspected.One topical null account, not a response rate. Other replies concern GHK-Cu and do not establish AHK injection effects or the claim that needling is required.
- Injecting AHK-Cu — plans and later uncertain outcomes (opens in a new tab)Actual Ok_Process3938 opening plan and visible follow-ups: 100 mg vial / 2 mg on five days per week, later 3 mg daily at about a month with minoxidil and continued shedding, then unsure it was doing anything. Glum-Push7346 injection-pain comparison and later bruising discussion also read.Unverified compounds and self-report; OP also posts a '2.5g' amount inconsistent with the mg posts, which is not normalized into a dose recommendation. GHK/AHK co-use and later ambiguous comparisons preclude a clean injection timeline.
What people say
- Hair density claims (human logs): Thicker look, baby hairs, less shed, or “thinning spots fill” over months of topical use — sparse, heavily confounded (minoxidil, needling, GHK, caffeine, lifestyle). forum
- Vs GHK-Cu (community cast): AHK cast as more follicle/DPC-niche; GHK as broader skin/ECM/wound literature. Marketing “AHK is upgraded GHK” is widely rejected by careful posters. forum
- Skin / matrix adjacency: Some facial/skin serum use by GHK analogy (tone, remodel talk) — far thinner AHK-specific skin trial base than GHK-Cu. forum
- What logs rarely claim: Acute stimulant feel, same-week density miracles, or clean unconfounded AGA reversal equal to minoxidil/finasteride standards. forum
- 2026 dual-copper DIY logs: 1 g AHK-Cu + 1 g GHK-Cu into The Ordinary (or HA) hair serum is a named 2026 mix; ~45-day “happy” posts exist — unblinded, often stacked with minox/dut. anecdote
- X hair-protocol lists: 2026 influencer stacks put AHK-Cu next to GHK-Cu, microneedling, and oral minox as a fin-avoid kit. Attribution is soup. forum
- Follicle elongation (ex vivo): Pyo 2007 — human occipital scalp follicles elongated significantly over ~12 days at AHK-Cu ~10⁻¹² to 10⁻⁹ M vs vehicle (p < 0.001 in secondary summaries). lab
- Dermal papilla growth: Same study — cultured human DPC proliferation increased (MTT) in the same low concentration band. lab
- Anti-apoptosis markers: At ~10⁻⁹ M, cleaved caspase-3 reduced ~42.7% and PARP cleavage fragments ~77.5% (both p < 0.05 in published secondary numbers); Bcl-2/Bax ratio shifted toward survival. lab
- Biphasic / high-dose inhibition: At ~10⁻⁸ M elongation was reduced (~15% class figures); at ~10⁻⁷ M inhibition was severe (~80% class figures in study summaries) — community uses this to argue against chasing ultra-high %. lab
- Honest gap: Controlled human scalp outcome data for standalone AHK-Cu topical remain thin; dish potency ≠ proven topical % or clinical hair-count wins. trial
- VEGF / TGF-β1 framing: Copper tripeptide complexes (including context for AHK/GHK) are discussed as raising VEGF and lowering TGF-β1 in fibroblast/DPC-adjacent writeups — used as the “blood supply + less regression signal” story. lab
Doses people talk about
- Route majority: Topical scalp/skin serum is the dominant community and cosmetic path. Concentration and application volume matter more than “mg injected.” forum
- Cosmetic supplier suggested use levels: Ingredient suppliers commonly list ~0.3–1% AHK-Cu in finished formulations (pre-dissolve in water; cool-down / <40 °C phase notes on some tech sheets). forum
- Commercial / finished-product cluster: Secondary guides often put finished scalp products around ~0.5–1% AHK-Cu (broader written band sometimes ~0.3–2%). forum
- 0.1–1% continuum: Some posters describe practical DIY anywhere from ~0.1% to ~1% depending on powder cost, irritation, and how aggressively they extrapolate from dish data. forum
- Illustrative high-end historical calc (forum, not trial): Scaling ~23.7 mg peptide per 0.25 mL of a 10% solution led some posters to aim ~2.5% with ~1 mL BID (~47 mg/day peptide) — expensive, irritation-prone, and unvalidated for AHK-Cu. forum
- Vendor marketing outliers: Some product pages quote 2–5% serum use or “max 10%” — treat as marketing/outliers relative to supplier 0.3–1% and careful DIY 0.1–1% clusters; higher % tracks with more irritation talk and contradicts biphasic dish caution. forum
- Application volume: Community logs range from a few drops (2–5) on thinning areas to ~0.25–1 mL per session for broader scalp coverage; volume × % determines milligrams delivered. forum
- Frequency: Once- or twice-daily leave-on scalp application is most named; evening-only routines are common when layered with other actives. forum
- Microneedling-day caution: Many guides discuss serum after needling, when channels are open, and ordinary daily strength rather than concentrated products. This is borrowed GHK/minoxidil needling culture, not AHK-specific PK or proof that the practice is safe. forum
- Injectable (minority, not mainstream): Sparse research-chem posts mention SC or local pin experiments (e.g. multi-mg every other day anecdotes). No clean community standard; topical remains the default recommendation in careful threads. anecdote
- Vendor inject charts (skeptical): Some peptide-shop pages invent 50–200 mcg or 1–2 mg “daily inject” tables for AHK — not backed by the 2007 follicle paper and not a consensus protocol. forum
- Purity / label flag: Gray-market “50 mg” or “10% stock” may not equal delivered copper complex; blue color is not a COA. Liposomal “10% solutions” sold for dilution need active-% math (e.g. diluting stock to a ~1% final). forum
- TikTok / vendor inject (not a study): 50–200 mcg, 0.5–1 mg, or 1–2 mg SC 3–5×/week charts circulate. Jan 2026 r/HairlossResearch OP planned 2 mg/day 5×/week from a 100 mg vial because TikTok said so. The cited follicle paper does not study injection; later OP updates report uncertain benefit with minoxidil co-use. forum
- Ordinary-serum mix: Dumping 1 g research powder into a finished multi-peptide hair serum is a 2026 DIY. Most posters do not actually check the resulting %. forum
- Higher historical forum math (HairLossTalk-era): Older threads debated ~2.5–5% w/v mixes and sometimes scaled application mass from non-AHK copper-peptide human/animal work (e.g. Trachy-era PC1031 2% and 10% solutions at 0.25 mL BID). Those % figures are not Pyo trial doses and are not AHK-specific RCTs — keep provenance separate. forum
- 2026 lower-DIY % cluster: Hair-loss/skincare forums 2012–2026 also quote daily scalp serums around ~0.05–0.2% — lower than many supplier 0.3–1% sheets. If stated as w/v, 0.05–0.2% is 0.5–2 mg/mL; the repeated ≈1–2 mg/mL comparison corresponds to 0.1–0.2%, not the entire band. Both are community; neither is a scalp RCT. forum
- Framing: Discussed DIY/research and cosmetic-supplier ranges only — not medical advice, not clinical protocols, not proof of optimal dose. AHK-Cu has no established human dose-finding for hair loss. forum
- Culture vs dish gap: Pyo 2007 worked at picomolar–nanomolar bath concentrations on isolated tissue (~10⁻¹²–10⁻⁹ M effective; higher inhibited). That does not translate cleanly to a topical % — barrier, vehicle, and local clearance dominate. lab
How it may feel
- Days 1–14: Early reports focus on application feel (tingle, cool, mild sting), dryness or temporary blue-green tint on skin/hair from copper, not an established density-change window. forum
- Weeks 2–4: Still too early for density calls in most hair diaries; irritation or product intolerance usually shows in this window if concentration/vehicle is wrong. forum
- Month 1 logs: Occasional “new hairs” or thicker feel claims appear in enthusiastic posts — still unblinded and often stacked; treat as anecdote. anecdote
- Months 2–3: Common first photo checkpoint borrowed from minoxidil-style hair culture, not from AHK RCTs. One July 2026 poster described new hairline hairs in the latest month after 2–3 months of daily topical use, while also using needling, long-term minoxidil and alfatradiol; another poster reported no change after about two months. forumanecdote
- Months 3–6: Sparse longer logs claim subtle thicken/shed shift, stable regrowth areas, or drop the experiment after no change. anecdote
- No change ~3–4 mo: Recheck consistent photos (same light/angle), vehicle/purity, application volume, needling hygiene, and stack confounds — not an automatic dose hike (biphasic in-vitro caution). forum
- After stop: Few clean washout logs; hard to separate from other hair treatments restarting or stopping. anecdote
- Inject minority feel: Rare SC/scalp-pin anecdotes describe gradual thickness or less shedding over weeks, but no established timeline or mainstream protocol. In the January 2026 thread, the OP later reported 3 mg daily at about a month, continued minoxidil-related shedding and uncertainty that AHK was doing anything. anecdote
- TikTok-pin first week (2026): Some inject logs describe less sting than GHK-Cu rather than density; the comparison is not consistent, with another commenter reporting worse injection pain. Hair-outcome discussion still runs over months, not a validated first-week effect. anecdote
- Female-inject caution (forum): Jul 2026 biohacking thread: “do not use injectable if female” — facial-hair worry, not a trial. forum
Around the dose
- Clock: Daily topical, often evening if vitamin C is a morning serum — copper peptides and ascorbic acid are a known mix fight. forum
- Scalp, not a gym pin: After shampoo, onto scalp not hair shaft, leave on. Not a pre-workout. forum
- Layering: Historical notes describe ~15–20 minutes before minoxidil, or the reverse order, to avoid premixing in one bottle; the checked culture study does not establish this as an AHK absorption interval. forumlab
- Needling day: Ordinary daily strength after rolling, rather than a 5% “max” on open channels, is a forum comparison—not established AHK safety guidance. Broken or infected skin, bleeding and procedure hygiene remain separate cautions. forum
- Photos, not vibes: Same light/angle at ~3 months. Biphasic dish data is why people do not treat “no change” as an automatic % hike. forum
- Don’t stack another copper peptide on a Glow/KLOW pin. Those blends already use GHK-Cu. forum
Cycles people discuss
- Hair judgment window: Continuous topical ~3–6+ months (often 12–16 weeks minimum before density calls) before photo-based decisions — hair-cycle clock, not acute PK. forum
- Daily vs pulsed: Continuous daily (or BID) leave-on use is the norm; no formal AHK on/off efficacy data. forum
- Cosmetic open-ended use: Finished copper-peptide hair/skin products are often used continuously like other actives until irritation or boredom. forum
- Irritation pause: Stop and reassess persistent redness, itch or burning. Historical notes discuss diluting or reintroducing a lower % after skin settles; the checked culture study does not validate a human restart strategy or tolerance law. This is not an instruction to restart. forumlab
- Seasonal restarts: Later seasons stacked with GHK-Cu, minoxidil, or needling appear in niche threads. forum
- Inject blocks (if any): Sparse; when mentioned, weeks-to-months of use then reassess — no standard on/off chart. anecdote
- Long-term safety DB: Thin for multi-year high-% DIY scalp or any injectable schedule. forum
Timing
- PK: A human half-life for intact AHK-Cu after topical scalp application or injection is not established by the sources checked here. Pyo 2007 studied isolated follicles and cultured cells, not drug clearance in people. forumlab
- Why daily topical is discussed: Forum rationale combines repeated scalp contact with multi-month hair-cycle observation. That is a routine and results-clock explanation, not measured local residence or plasma-depot evidence. forum
- Timing of day: Evening or steady 1–2× daily; no controlled timing trials. Some separate minoxidil morning and copper evening. forum
- Layering wait: Historical practical discussion names ~15–20 minutes between copper serum and minoxidil, in either order, to give each scalp contact and avoid premixing. The checked culture study does not measure this layering interval or establish a chemistry safeguard. forumlab
- Stability vs PK: Mixed-serum shelf life (oxidation, light, contamination) often sets batch size more than true pharmacokinetics. forum
- Results clock: Density talk is weeks-to-months of repeated use; dish follicle elongation was measured over days in culture — different system. lab
- Biphasic biology reminder: Historical study summaries report inhibition at excess culture concentrations. The checked culture abstract does not establish a useful human scalp concentration, residence time or dosing interval, with or without irritation. lab
More on what it is
- Why people search it: Hair/scalp forums and DIY copper-peptide culture orbit a 2007 Seoul National University paper (Pyo et al., Arch Pharm Res; PMID 17703734) on cultured human follicles and dermal papilla cells. forum
- Research lens: Separate (1) Pyo dish data, (2) cosmetic finished products with listed use levels, (3) gray-market powder DIY serums, (4) rare inject anecdotes — they are not one evidence ladder. forum
- 2026 inject vs topical: r/HairlossResearch (Jan 2026) and r/Biohacking (Jul 2026) still get “should I pin this?” — TikTok 2 mg/day charts vs “mix the powder into a serum.” No published AHK-Cu injection study. forum
- INCI honesty: Copper tripeptide-3 is AHK-Cu; copper tripeptide-1 is GHK-Cu. A bottle that just says “copper peptides” is usually GHK. forum
- What it is: Synthetic copper-binding tripeptide (L-alanyl-L-histidyl-L-lysine complexed with Cu²⁺). In cosmetic-ingredient talk it is often labeled copper tripeptide-3. Molecular weight commonly cited ~416 g/mol (≈415.9 in supplier datasheets). trial
- Vs GHK-Cu structure: Same His-Lys-Cu scaffold; N-terminal glycine (GHK) is swapped for alanine (AHK) — one methyl group difference. GHK-Cu is endogenous (human plasma); AHK-Cu is synthetic. trial
- Mechanism talk (that paper): Follicle elongation and dermal papilla cell (DPC) proliferation at very low concentrations; anti-apoptosis markers (Bcl-2/Bax up, caspase-3 and PARP cleavage down); copper-peptide literature also frames raised VEGF and lowered TGF-β1 as supporting longer anagen / better follicle support. lab
- Biphasic honesty: In the same dish model, higher concentrations inhibited elongation — “more is not better” is a real study finding, not just forum caution. lab
- Evidence ceiling: Strongest AHK-specific data is ex-vivo/in-vitro. Modern controlled human scalp RCTs for standalone AHK-Cu remain sparse; much “works like copper peptides” talk is borrowed from GHK-Cu or multi-ingredient products. trial
- Not the same as: GHK-Cu, minoxidil, finasteride/dutasteride, steroids, Tricomin/PC-class copper peptides used in older ProCyte-era trials, or an FDA-approved hair-loss drug. trial
Stacks
- + GHK-Cu (dual copper): Most named peptide stack — “follicle-niche AHK + broader matrix GHK” rationale. Example community starts: ~1% AHK-Cu + ~1–2% GHK-Cu in the same water-based bottle (e.g. 1 g each into 100 mL HA serum). Not a combo RCT. forum
- + Microneedling: Serum + scalp rolling/stamping for penetration. Community depths often ~0.5–1.5 mm; cadence from ~weekly to every ~10 days (some more aggressive — higher risk). Needling evidence base is largely minoxidil/AGA studies and general copper-peptide microneedling work, not AHK-only trials. forum
- + Minoxidil: Very common co-use; mechanisms framed as different (vasodilation/anagen support vs copper-peptide DPC/VEGF talk). Outcome credit heavily confounded. Prefer separate application timing if worried about vehicle chemistry. forum
- + Finasteride / dutasteride / RU-style anti-androgens: Standard AGA stacks with copper serum as adjunct — attribution nearly impossible. forum
- + Caffeine / scalp massage / coffee-ground exfoliation: Appears in the same enthusiast threads as AHK; blood-flow/exfoliation confounds. forum
- + Spironolactone topical (historical forum stacks): Older HairLossTalk-style multi-agent days; irritation and schedule complexity rise. forum
- Skincare base hygiene: Moisturizer/SPF for face use; rotate away from strong acids/retinoids same window when tolerance is limited. forum
- Glow / KLOW note: Named multi-peptide inject blends (GLOW/KLOW) use GHK-Cu, not AHK-Cu, as the copper leg — do not assume AHK substitutes 1:1 in those vials. forum
- Not usually stacked for: Same-syringe inject cocktails with random research peptides — AHK is not a standard inject blend component. forum
Access talk
- Not on the July 2026 peptide ballot. PCAC that week was BPC/KPV/TB-500 and neighbors. AHK-Cu is not that story. trialforum
- Three products, one nickname: Cosmetic copper tripeptide-3 serum, gray 1 g DIY powder, and “injectable” 100 mg RUO vials. They are not one evidence ladder. forum
- Blue is not a COA. Color, “10% stock,” and a TikTok pin chart do not prove identity or sterility. forum
- Glow/KLOW copper is GHK-Cu. Do not assume AHK substitutes 1:1 in those vials. forum
Storage notes
- No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
- Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum
Watch for
- Local irritation: Redness, sting, itch, dryness, flaking — most named topical downside; worse at high DIY % or on broken/needled skin. forum
- Blue-green tint: Temporary staining of skin/hair/pillow from copper ion is cosmetic nuisance, not proof of efficacy. forum
- Needling add-ons: Bleeding, infection/hygiene fails, over-needling scarring risk — procedure risks independent of peptide. forum
- Premix chemistry: Ethanol/PG minoxidil + copper peptide long-term mixes are forum-flagged for peptide degradation; separate bottles reduce that variable (not a safety guarantee). forum
- Evidence gap risk: Thin human outcome data → months of useless or irritating regimens on hope; photo discipline matters. forum
- Injectable unknowns: Systemic copper load, off-target hair growth anxiety, and sterility issues — rare anecdotes only, no safety database. anecdote
- DIY ≠ cosmetic heritage: Finished copper cosmetics and supplier use-levels do not validate gray-market research powders or inject protocols. forum
- Theoretical copper accumulation: Heavy long-term high-exposure use has not been well characterized in humans for AHK-specific regimens. forum
- Broken / infected skin: Avoid applying research serums to open infection or poorly healing scalp wounds. forum
- Pregnancy / lactation / pediatric: Essentially no safety data in research-use contexts — treated as avoid in careful writeups. forum
- TikTok pin ≠ dish paper: Borrowing GHK-Cu milligrams or a 2 mg/day SubQ chart does not create an AHK-Cu safety package. Sterility and copper load are extra unknowns. forum
- Contact allergy / copper sensitivity: Copper can sensitize; a 2014 contact-dermatitis review (PMID 25098945) reported positive copper patch-test reactions in roughly ~3.8% of tested subjects — class risk, not AHK-specific trial rate. Stop-and-reassess if dermatitis. trial
- Biphasic / counterproductive high dose: Dish data showed inhibition at higher molar concentrations — chasing 5–10% “max” serums is not supported by the foundational follicle paper. lab
- Not a proven AGA drug: Calling standalone AHK-Cu a validated clinical hair-loss treatment overstates evidence versus minoxidil/finasteride standards. trial
Evidence mix
Mostly community / anecdote tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.